Trial Profile

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ticagrelor (Primary) ; Clopidogrel
Indications Cardiovascular disorders; Myocardial infarction; Peripheral arterial disorders; Stroke
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms EUCLID
Sponsors AstraZeneca

01 Feb 2022 Results of a post hoc analysis assessed the world regional differences in outcomes published in the Vascular Medicine
01 Feb 2022 Results published in the Journal of Vascular Surgery
18 Feb 2020 Results of post-hoc analysis were published in the Journal of the American College of Cardiology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com